COPENHAGEN, Denmark--(BUSINESS WIRE)--Symphogen A/S announced today that it has entered into a global strategic collaboration with Genentech, Inc. for antibody therapeutics against three undisclosed infectious disease targets.
COPENHAGEN, Denmark--(BUSINESS WIRE)--Symphogen A/S announced today that it has entered into a global strategic collaboration with Genentech, Inc. for antibody therapeutics against three undisclosed infectious disease targets.
